TATAM RCT Demonstrates Superior Angiographic Outcomes with Transvenous Embolization in Stroke Management – Stroke AHA/ASA
Stroke AHA/ASA posted on X:
“RCT results show that transvenous embolization is more effective than transarterial embolization in terms of angiographic results at 3-6 months, with comparable morbidity.”
Title: Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations: A Randomized Comparison With Transarterial Embolization.
Autors: Jean Raymond, Tim E. Darsaut, Suzana Saleme, Aymeric Rouchaud, Daniela Iancu, Daniel Roy, Alain Weill, Leonardo Olijnyk, Roland Jabre, Michel W. Bojanowski, Chiraz Chaalala, David Roberge, Kamel Boubagra, Olivier Heck, Jeremy L. Rempel, Chrysanthi Papagiannaki, Xavier Barreau, Gaultier Marnat, Jean-Christophe Gentric, Julien Ognard, Lorena Nico, Marc Bintner, Pascale Gauthier Lasalarie, Jean-Brice Veyrieres, Michel Piotin, Simon Escalard, Vitor M. Pereira, Daniel G. Abud, Justine Zehr, Miguel Chagnon, Thanh N. Nguyen, David Mathieu, Guylaine Gevry, BSc, Ruby Klink, Emmanuelle Lorian, Charbel Mounayer, TATAM Collaborative Group.
Full article via AHA Journals
Brief Analysis: TATAM RCT Findings
The TATAM randomized controlled trial compared transvenous embolization (TVE) versus transarterial embolization (TAE) in patients requiring endovascular intervention for cerebrovascular malformations.
Key Finding:
TVE demonstrated superior angiographic occlusion rates at 3–6 months follow-up, indicating more effective lesion closure.
Clinical Impact:
Despite a more technically complex route, TVE maintained morbidity rates comparable to TAE, supporting its safety profile.
Implication:
TVE may become the preferred embolization strategy for select cerebrovascular lesions, offering enhanced efficacy without increased risk.
See more in Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 01:37Flora Peyvandi on Iron Deficiency in Mild to Moderate Bleeding Disorders
-
Sep 12, 2025, 07:28Lauren Murphy: Platelets as DNA “Sponges”
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 12, 2025, 07:54Aurelio Maggio Thanks Contributors to Webinar on Advanced Treatments in Rare Blood Disorders
-
Sep 12, 2025, 07:20Women for Their Health: Paige Bingham on Boston Scientific's Initiative ''Close the Gap'' Act During AFib Awareness Month
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births